Personalizing Medicine through AI

Our Approach

Focused on Changing Breast Cancer Outcomes

PreciseDx® is dedicated to supporting more personalized and precise treatments for breast cancer.

 

On average, every two minutes a woman is diagnosed with breast cancer in the United States.

About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.

About PreciseDx

PreciseDx® is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.

Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists

Better Data. Better Outcomes.

PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.

  • Patients
  • Providers
  • Payers
  • BioPharma

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Patients

The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.

Providers

For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.

Payers

By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.

BioPharma

The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.

Gold Corporate Member
Jack Zeineh, PreciseDx
Gold Corporate Member

Featured News & Resources

Press Release
May 29, 2024
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
Press Release
May 28, 2024
PreciseDx Announces Poster Presentation at The 2024 American Society of Clinical Oncology Annual Meeting
Media Alert
May 1, 2024
PreciseDx to Attend the 2024 FLASCO Oncology Business Summit & Spring Session

Interested in Learning More?

Contact Us